Nicox S.A. Advances in Ophthalmic Therapies Amid Market Fluctuations

Nicox S.A., a prominent health care biotechnology company based in Valbonne, France, continues to make strides in the development and marketing of therapies targeting various ophthalmic conditions. As of August 5, 2025, the company’s stock is trading at 0.522 EUR on the NYSE Euronext Paris, with a 52-week high of 0.566 EUR and a low of 0.14 EUR recorded on September 12, 2024. The company’s market capitalization stands at 25,370,000 EUR, and it operates with a price-earnings ratio of -1.687.

Nicox’s product pipeline is diverse, focusing on innovative treatments for eye-related conditions. Key products include Vyzulta™, an intraocular pressure-lowering treatment, and NCX 470, a nitric oxide (NO)-donating candidate aimed at treating glaucoma. Additionally, the company is developing stand-alone NO donors for specific applications in ophthalmic diseases. ZERVIATE, an eye drop formulation of cetirizine, is designed for allergic conjunctivitis, while NCX 4280 targets morning ocular congestion. NCX 4251, a patented formulation of fluticasone propionate, is intended for the treatment of blepharitis.

The company’s collaborative efforts are noteworthy, with partnerships established with industry giants such as Bausch + Lomb, AstraZeneca, Merck, Pfizer, and Ironwood Pharmaceuticals, Inc., as well as Novaliq GmbH. These collaborations are pivotal in advancing Nicox’s research and development initiatives.

Founded in 1996, Nicox has established itself as a key player in the biotechnology sector, particularly within the health care industry. The company’s commitment to innovation and strategic partnerships underscores its dedication to addressing unmet medical needs in ophthalmology.

For more detailed information about Nicox’s ongoing projects and financial performance, stakeholders and interested parties can visit the company’s website at www.nicox.com . Nicox remains listed on both the NYSE and Euronext Paris stock exchanges, reflecting its international presence and influence in the biotechnology landscape.